论文部分内容阅读
目的探讨伊立替康联合顺铂治疗初治晚期食管癌的疗效和安全性。方法 34例初治晚期食管癌患者应用伊立替康65 mg/m2,静脉滴注;顺铂30 mg/m2,静脉滴注;第1、8、15、22天,每6周为一周期,每6周疗效评价一次。结果全组34例患者均可评价疗效,CR 1例,PR 18例,SD 10例,PD 5例,有效率55.9%,中位生存期为13.9个月,中位肿瘤进展时间为6.3个月。结论伊立替康联合顺铂治疗初治晚期食管癌疗效显著,耐受性良好,安全性高,改善患者的生活质量,该方案值得在临床中进行推广。
Objective To investigate the efficacy and safety of irinotecan combined with cisplatin in the treatment of newly diagnosed advanced esophageal cancer. Methods 34 patients with newly diagnosed advanced esophageal cancer were treated with irinotecan 65 mg / m2 intravenously; cisplatin 30 mg / m2, intravenously; on the first, the 8th, the 15th and the 22nd, Evaluation every 6 weeks. Results All 34 patients could evaluate the curative effect. The CR was 1, PR 18, SD 10 and PD 5, the effective rate was 55.9%, the median survival time was 13.9 months and the median tumor progression time was 6.3 months . Conclusion The combination of irinotecan and cisplatin in the treatment of advanced esophageal cancer has significant curative effect, good tolerability, high safety and quality of life, which is worth to be popularized in clinic.